Brazil cases shed more light on COVID-19 reinfection risk
Researchers believe reinfection with SARS-CoV-2 may be more common than previously thought, after an analysis of people contracting COVID-19 twice.
Working with local biotech, University of Toronto to test drug that may prevent fatal...
The University of Toronto has partnered with Markham, Ont.-based Edesa Biotech on laboratory studies of a drug that physicians are already using at Canadian hospitals in a clinical...
UM survey shows over 60 per cent of Macao residents intent to receive COVID-19...
A research team from the University of Macau (UM) Institute of Chinese Medical Sciences (ICMS) recently conducted a survey on the intention of Macao residents to receive COVID-19 vaccine and its influencing factors in Macao.
Duke Researchers Receive Grant to Roll Out Next-Generation Coronavirus Vaccine
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded $17.5 million over three years to the Duke Human Vaccine Institute to develop a vaccine that protects against multiple types of coronaviruses and viral variants.
Recruitment commences for Phase 1 clinical trial of two Melbourne-made COVID-19 vaccines
Melbourne researchers are calling on healthy people aged 18-70 living in Victoria to roll up their sleeves for a Phase 1 clinical trial of two Melbourne-made COVID-19 vaccines.
Surgical masks as good as N95 masks for health-care workers providing routine COVID-19 care
Surgical masks are not inferior to N95 masks for preventing the spread of COVID-19 to health-care workers, says a study led by McMaster University researchers.
Religious people coped better with Covid-19 pandemic, research suggests
Two Cambridge-led studies suggest that the psychological distress caused by lockdowns (UK) and experience of infection (US) was reduced among those of faith compared to non-religious people.
QUT Advance Queensland COVID-19 Industry Research Fellowships
Seven QUT researchers have been awarded Advance Queensland Industry Research Fellowships in a round of research funding focused on COVID-19.
Coronavirus antibodies last at least three months after infection, University of Toronto study finds
Coronavirus antibodies can last at least three months after a person becomes infected with the virus that causes COVID-19, according to a study published in Science Immunology.
Online job advertisements continue to bounce back
Looking for a job? The COVID-19 impact on the Australian labour market has been daunting and dispiriting, but as we round out the year, online job vacancies are increasing.
